Company intelligence / Profile preview

B-Temia

St-Augustin-de‑Desmaures, Quebec, Canadab-temia.com ↗

Ownership: Private
Development stage: Commercial

Overview

B‑Temia's flagship product Keeogo has demonstrated safety and effectiveness in assisting gait quality and autonomy for people with neurological or musculoskeletal impairments. A multi-site interventional trial evaluated its use for hemiparesis after stroke.

Therapeutic areas: OtherRheumatologyNeurology
Modalities: DeviceRoboticsArtificial intelligence-enabled device
Industry: Assistive Medical Devices

Drug pipeline

1 asset

Keeogo

Commercial

Indications: Mobility disorders, Rehabilitation

Partnerships

Wistron Corporation – manufacturing/commercialization partner & major shareholderLockheed Martin – co-development of ONYX exoskeleton for US ArmyOssur – distribution of Keeogo in EU countries since 2023DIH – distribution of Keeogo in North America since 2024

Beyond the preview

Go deeper on B-Temia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-Temia.

Explore the full profile